Clinical Trial Update: Physiological Intermolecular Modification Spectroscopy (PIMS) in Ulcerative Colitis With Golimumab [Phase 4]

View source ↗

Summary

A Phase 4 clinical trial update evaluating Golimumab for ulcerative colitis, incorporating Physiological Intermolecular Modification Spectroscopy (PIMS) as part…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Simponi (golimumab)

Snippet

Sponsor: Kliniken im Naturpark Altmuehltal | Conditions: Ulcerative Colitis | Phase 4 | Status: UNKNOWN